Sugi Predict

Sugi Predict / Compounds / SCHEMBL677962

SCHEMBL677962

SCHEMBL677962

NS(=O)(=O)c1ccc(N2CCCC2=O)c([N+](=O)[O-])c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 1.00
▸ GAA P10253 2/20 1.00
▸ HTT P42858 3/20 0.76
▸ ALDH1A1 P00352 3/20 0.76
▸ MAPT P10636 4/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ HPGD P15428 1/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ CYP1A2 P05177 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2D6 P10635 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ CA2 P00918 6/20 0.49
▸ CA1 P00915 5/20 0.49
▸ CA9 Q16790 5/20 0.49
▸ CA12 O43570 3/20 0.49
▸ VCAM1 P19320 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25433246 0.85 KDM4E (0.73) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL23466602 0.80 SMN1; SMN2 (0.67) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL29758010 0.80 SMN1; SMN2 (0.67) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL2480089 0.78 KDM4E (0.60) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL29805501 0.75 KDM4E (0.60) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL16038620 0.73 MAPT (0.75) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL1959129 0.73 MAPT (0.75) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL28153181 0.73 MAPT (0.75) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL23850476 0.73 KDM4E (0.57) KDM4EGAAHTTALDH1A1MAPT
SCHEMBL31588134 0.73 KDM4E (0.57) KDM4EGAAHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 — — EP disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 — — US disclosed
CN-115193415-A Moisture fluctuating CO with enhanced capacity and kinetics 2 Adsorbent and method of making same 帕洛阿尔托研究中心公司 2022-10-18 — — CN disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 — — US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 — — US disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 — — US disclosed
US-20200278346-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ADJACENT ACQUISITION CO., LLC 2020-09-03 — — US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20150309021-A1 Advanced Drug Development and Manufacturing LOS ALAMOS NATIONAL SECURITY, LLC 2015-10-29 — — US disclosed
EP-2511844-B1 X-ray microscope XRPRO SCIENCES INC (US) 2015-08-12 — — EP disclosed
WO-2007134077-A2 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2007-11-22 — — WO disclosed
US-20070270449-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2007-11-22 — — US disclosed
US-20070244143-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS BRAINCELLS, INC (US) 2007-10-18 — — US disclosed
WO-2007104035-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS BRAINCELLS, INC. (US) 2007-09-13 — — WO disclosed
US-20070208029-A1 MODULATION OF NEUROGENESIS BY PDE INHIBITION BRAINCELLS, INC. (US) 2007-09-06 — — US disclosed
US-20070112017-A1 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2007-05-17 — — US disclosed
WO-2007053596-A1 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2007-05-10 — — WO disclosed
WO-2007047978-A2 MODULATION OF NEUROGENESIS BY PDE INHIBITION BRAINCELLS, INC. (US) 2007-04-26 — — WO disclosed
US-20070078083-A1 MODULATION OF NEUORGENESIS BY HDac INHIBITION BRAINCELLS, INC. (US) 2007-04-05 — — US disclosed
WO-2007030697-A2 MODULATION OF NEUROGENESIS BY HDAC INHIBITION BRAINCELLS, INC. (US) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112017-A1 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS GABRB2, GAP43, GABRB1 KDM4E 3176/4885GAA 2176/4885HTT 987/4885
US-20070270449-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR5A, HTR6, GAP43 KDM4E 3193/4885GAA 3616/4885HTT 327/4885
US-20070078083-A1 MODULATION OF NEUORGENESIS BY HDac INHIBITION DCX, BDNF, NTRK2 KDM4E 1039/4885GAA 1001/4885HTT 1921/4885
US-20070208029-A1 MODULATION OF NEUROGENESIS BY PDE INHIBITION PDE2A, PDE4A, DCX KDM4E 2169/4885GAA 1193/4885HTT 1638/4885
US-20070244143-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS GAP43, BDNF, DCX KDM4E 2859/4885GAA 3519/4885HTT 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.